Falk Gastro Info 8/2016

Video report

Video course abdominal ultrasound

Pelvis, lymph node evaluation

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:

Bowel

Text:

Ben-Horin S et al, Gut. 2016;65(7):1132–8

Infliximab biosimilars: Anti-Remicade^® antibodies in IBD patients similarly recognize and functionally inhibit the biosimilar Remsima^®.

Link to text

Text:

Ananthakrishnan AN et al, Clin Gastroenterol Hepatol. 2016;14(7):973–9

Colorectal cancer in IBD patients: Statin use is associated with reduced risk of tumorigenesis.

Link to text

Text:

Aziz I et al, Clin Gastroenterol Hepatol. 2016;14(5):696–703.e1

Irritable bowel syndrome with diarrhea: A dietitian-led gluten free diet provided sustained benefit to patients with IBS-D, which may be partially influenced by their HLA-DQ status.

Link to text

Liver Biliary Tracts

Text:

Pan CQ et al, N Engl J Med. 2016;374(24):2324–34

Hepatitis B: Tenofovir therapy in pregnant women with high hepatitis B viral load during the third trimester (HBe antigen-positive, HBV DNA level > 200,000 IU/ml) reduces the risk of mother-to-child transmission of hepatitis B virus infection.

Link to text

Text:

Peveling-Oberhag J et al, J Viral Hepat. 2016;23(7):536–44

Hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (B-NHL): A current meta-analysis demonstrates a high remission rate of HCV-associated B-NHL after antiviral therapy. Antiviral therapy may thus be first-line therapy in HCV-associated B-NHL not requiring immediate conventional chemotherapy.

Link to text

Text:

Ratziu V et al, Gastroenterology. 2016;150(5):1147–59.e5

Non-alcoholic steatohepatitis (NASH): In a current randomized, double-blind, placebo-controlled trial, elafibranor, an agonist of the peroxisome proliferator-activated receptor-a and -d, induced resolution of non-alcoholic steatohepatitis (NASH) without fibrosis worsening. However, results were significant in a post-hoc modified analysis only, indicating that additional studies need to confirm a benefit of elafibranor.

Link to text

Oesophagus Stomach Duodenum

Text:

Philpott H et al, Aliment Pharmacol Ther. 2016;43(9):985–93

Eosinophilic esophagitis: Approx. half of EoE patients respond to elimination diet and PPI while only 1 in 4 patients will maintain remission over 9 months. Budesonide is very effective short term, but longer term study is needed.

Link to text

Text:

Mooney PD et al, Gastroenterology. 2016;150(5):1125–34

Celiac disease: Biopsies from the duodenal bulb increase the sensitivity for the detection of celiac disease. Approx. 10% of celiac disease patients in this trial had ultra-short celiac disease limited to the duodenal bulb, which resulted in a rather mild clinical phenotype.

Link to text

Text:

Kestens C et al, Clin Gastroenterol Hepatol. 2016;14(7):956–62.e1

Barrett’s esophagus: Low-grade dysplasia is often not confirmed by a second pathologist and frequently lost during follow-up. However, patients with confirmed and persistent low-grade dysplasia have an increased risk of malignant progression.

Link to text

Pancreas

Text:

Luo H et al, Lancet. 2016;387(10035):2293–301

Post-ERCP pancreatitis: Compared with a risk-stratified post-procedural strategy, pre-procedural administration of rectal indomethacin in unselected patients reduces the overall occurrence of post-ERCP pancreatitis.

Link to text

International Symposia and Workshops

Symposium 204

Clinical Hepatology Practice in 2016: From Science to Therapy

September 2 – 3, 2016, Birmingham, United Kingdom

The ICC Birmingham, International Convention Centre, Broad Street, B1 2EA Birmingham, Great Britain

Program

Registration

Online registration

Gastroenterology Symposium

Putting the Puzzle Together: Inflammation and Gastrointestinal Disease

September 16 – 17, 2016, Regensburg, Germany